Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Global incidence and prevalence of nonalcoholic fatty liver disease

Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah

Clin Mol Hepatol. 2023;29(Suppl):S32-S42. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0365

View: 10813 Download: 452 Web of Science: 92 Crossref: 119

Editorial

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?

Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang

Clin Mol Hepatol. 2023;29(2):404-407. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0069

View: 2911 Download: 79 Web of Science: 2 Crossref: 2

Original Article

Global prevalence of depression and anxiety in patients with hepatocellular carcinoma: Systematic review and meta-analysis

Darren Jun Hao Tan, Sabrina Xin Zi Quek, Jie Ning Yong, Adithya Suresh, Kaiser Xuan Ming Koh, Wen Hui Lim, Jingxuan Quek, Ansel Tang, Caitlyn Tan, Benjamin Nah, Eunice Tan, Taisei Keitoku, Mark D. Muthiah, Nicholas Syn, Cheng Han Ng, Beom Kyung Kim, Nobuharu Tamaki, Cyrus Su Hui Ho, Rohit Loomba, Daniel Q. Huang

Clin Mol Hepatol. 2022;28(4):864-875. Published online July 25, 2022

DOI: https://doi.org/10.3350/cmh.2022.0136

View: 5855 Download: 133 Web of Science: 10 Crossref: 10

Review

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):790-801. Published online May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0070

View: 7308 Download: 494 Web of Science: 43 Crossref: 44

1 |

Viewed By 5664	MAFLD: How is it different from NAFLD?
Viewed By 5579	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5387	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5338	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4991	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 119	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 91	MAFLD: How is it different from NAFLD?
Cited By 82	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search